Stocktoria
Tyra Biosciences, Inc. TYRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-09-15
Tyra Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M |
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M |
| Income tax | $0 | $0 | $0 | $2,000 | $1,000 |
| Net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M |
| EPS (diluted) | $-2.01 | $-1.51 | $-1.62 | $-1.32 | $-1.91 |
| Operating cash flow | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M |
| Free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M | -$24.4M |
| Cash & equivalents | $77.4M | $92.0M | $58.0M | $251.2M | $302.2M |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.4M | $5.0M |
| Shareholders' equity | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M |
Source: SEC EDGAR filings · CIK 0001863127 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.